FDA Experience With Regulation of Naloxone Products to Address the Opioid Crisis and Opportunities for Leveraging Scientific Engagement.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin Pharmacol Ther

Title: Clinical pharmacology and therapeutics

Publisher: Wiley

ISSN (Electronic): 1532-6535

ISSN (Print): 0009-9236

Publication date (Electronic): Mar 2021

Volume: 109

Issue: 3

Affiliations

[1 ] Science and Research Team, Office of Translational Sciences, Center for Drug Evaluation and Research, US, Food and Drug Administration, Silver Spring, Maryland, USA.

[2 ] Division of Neuropsychiatric Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

[3 ] Hertz and Fields Consulting, Inc., Silver Spring, Maryland, USA.

[4 ] Division of Anesthesia, Addiction Medicine and Pain Medicine (DAAP), Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

[5 ] Strategic Partnerships, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Article

DOI: 10.1002/cpt.2086

PubMed ID: 33241562

SO-VID: 29ce6610-0d07-4604-92a6-dbded14446c2

History

Data availability:

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Cited by 2

See all cited by